Posted by Michael Wonder on 03 Oct 2017
Why Brexit could make the U.S. a refuge for sick Europeans lacking drug access
2 October 2017 - As Britain prepares to leave the European Union, the EMA is preparing to move from its London headquarters.
The agency is responsible for evaluating new medications, so the move leaves EU citizens in limbo where accessing drugs—both new and already approved—is concerned.
Nineteen EU cities are vying to be the future home of the EMA. On Saturday, the European Commission released a study on the impacts of these 19 cities, prioritising each based on six criteria, including the assurance that the agency’s operations will continue after the UK leaves the EU in March 2019.
